Antibody Drug Conjugate Market Analysis - Forecast(2021 - 2026)

Report Code: HCR 0152 Report Format: PDF + Excel (Delivery in 48 Hrs)

Antibody Drug Conjugate Market Overview

Antibody Drug Conjugate Market size is estimated to reach $3,356.1 Million by 2025, growing at a CAGR of 14.1% during the forecast period 2020-2025. Antibody drug conjugates or ADCs are the bio-pharmaceutical drugs that are used in the treatment of cancer. This antibody drug conjugates are used to kill the tumor cells while protecting the healthy cells in the body. According to reports, there are 56 pharmaceutical companies developing antibody drug conjugates in 2019. By the technology advancement in the medical field, the monoclonal antibodies are linked with the cytotoxic drugs to target the tumors. The increase in the aging population, prevalence of cancer, and an increase in the obese population are some of the factors that are causing growth to the market during the forecast period 2020-2025. Even though there are large number of pharmaceutical companies the success rate in antibody drug conjugates is very less and limited to very few companies, company with good development have a booming market during the forecast period 2020-2025.

Antibody Drug Conjugate Market Report Coverage

The report: “Antibody Drug Conjugate Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Antibody Drug Conjugate Market. 
By Product: Adcertis, Kadcyla and Others
By Type: Monoclonal antibodies, Linker, Drug/Toxin, and Others
By Application: Blood cancer, Ovary cancer, Lung cancer, Skin cancer, Breast cancer, Brain tumor and Others
By End-Users: Hospitals, Specialized cancer centers, Academic research institutes, Biotechnology companies, and Pharmaceutical companies,
By Geography: North America, Asia-Pacific, Europe, and Rest of the World

Key Takeaways

  • Geographically, North America’s Antibody Drug Conjugate Market accounted for the highest revenue share in 2019 and it is poised to dominate during the forecast period 2020-2025 owing to increased number of patients having different types of cancers..
  • The increase prevalence of cancers and an increase in need for best drug instead of chemotherapy is driving the manufacturers to develop new antibody conjugates for the better treatment of cancer.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Antibody Drug Conjugate Market report.
  • The increase in partnership and collaboration between different research centers and pharmaceuticals, increase in advance drug discovery are driving the growth of the antibody drug conjugate market.

By Product - Segment Analysis

The Product segment of Antibody Drug Conjugate Market has Adcertis, Kadcyla and Others. The Kadcyla segment registers for the highest market share in 2019 and is set to continue for the forecast period 2020-2025 with a CAGR of 14.1%, owing to the increased number of breast cancers globally. Trastuzumab emtansine is also known as ado-trastuzumab emtansine, has a trade name Kadcyla is an antibody drug conjugate which is used in the treatment of the HER2-positive metastatic breast cancer in patients.  Adcetris, the trade name of Brentuximab vedotin having an application in the treatment of the relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma, these applications are driving the antibody drug conjugate market in this segment during the forecast period 2020-2025.

By Application - Segment Analysis

The Application segment of the Antibody Drug Conjugate Market has Blood cancer, Ovary cancer, Lung cancer, Skin cancer, Breast cancer, Brain tumor and Others. The Blood cancer segment which is sub-divided into Leukemia, Lymphoma, Multiple myeloma, registers for the highest market share in 2019 and is set to continue for the forecast period 2020-2025, owing to the increased number of people suffering from different types of cancers. The breast and lung cancer segments are also set to have the fastest growth during the forecast period 2020-2025. According to WHO reports of 2018, it is set to be that out of 6 death in the world one is owing to cancer. The lung and breast cancers are top in the global cancer effected patients with about 2.09 million people per each cancer type. The availability of antibodies like Kadcyla is driving the growth of the market for breast cancers segment during the forecast period 2020-2025.

By Geography - Segment Analysis

Based on Geography the global Antibody Drug Conjugate Market is segmented into North America, Europe, Asia-Pacific and the Rest of the World. North America had a dominant share in terms of revenue in 2019 and it holds the largest market share of 41.3% during the forecast period 2020-2025, owing to the availability of the large number of key players in this region. Owing to growing population and rising in different types of cancers are boosting the growth of antibody drug conjugates in the Asia-pacific region. The rising awareness among the people, increased health care infrastructure and an increase in funding the government and private sector are driving the market in different regions globally during the forecast period 2020-2025.

Drivers – Antibody Drug Conjugate Market

  • High prevalence of cancer

The increase in diseases like blood cancers, lung cancer, breast cancer and other types of cancers are driving the growth of the antibody drug conjugate market during the forecast period 2020-2025.

Challenges – Antibody Drug Conjugate Market

  • High cost of procedures

The cost involved in the manufacturing and clinical trials of the antibody drug conjugate is hampering the growth of the market. The lack of funds and having less success rate in making of the antibody conjugates are challenging the market growth during the forecast period 2020-2025.

Antibody Drug Conjugate Industry outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antibody Drug Conjugate Market. Key companies of this market are Genentech, ImmunoGen, Inc., Seattle Genetics, Concortis Biotherapeutics, Immunomedics, Pfizer Inc., Bayer HealthCare, Synthon, Agensys, Inc, Celldex Therapeutics and Others.

Acquisitions/Product Launches:

  • In June 2019, Seattle Genetics, Inc. has got FDA approval for the Polivy (Polatuzumab vedotin-piiq), a antibody drug conjugate, which is used in adults for the treatment of B-cell lymphoma.
  • In January 2019, Immunomedics Inc., has collaborated with the AstraZeneca for the study on combination of Imfinzi against PD-L1, whereas the Imfinzi is a human monoclonal antibody. And this study is to develop new antibody drug conjugate for breast cancer.
1. Antibody Drug Conjugate Market - Overview
    1.1 Definitions and Scope
2. Antibody Drug Conjugate Market - Executive Summary
    2.1 Market Revenue 
    2.2 Key trends by Product
    2.3 Key trends by Type
    2.4 Key trends by Application
    2.5 Key trends by End-Users
    2.6 Key trends by Geography
3. Antibody Drug Conjugate Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies 
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Antibody Drug Conjugate Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Antibody Drug Conjugate Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Antibody Drug Conjugate - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Antibody Drug Conjugate Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Antibody Drug Conjugate Market – By Product (Market Size –$Million/$Billion)
    8.1 Adcertis
    8.2 Kadcyla
    8.3 Others
9. Antibody Drug Conjugate Market – By Type (Market Size –$Million/$Billion)
    9.1 Monoclonal antibodies
    9.2 Linker
    9.3 Drug/Toxin
    9.4 Others.
10. Antibody Drug Conjugate Market – By Application (Market Size –$Million/$Billion)
    10.1 Blood cancer
        10.1.1 Leukemia
        10.1.2 Lymphoma
        10.1.3 Multiple myeloma
    10.2 Ovary cancer,
    10.3 Lung cancer, 
    10.4 Skin cancer
    10.5 Breast cancer, 
    10.6 Brain tumor
    10.7 Others
11. Antibody Drug Conjugate Market – By End-Users (Market Size –$Million/$Billion)
    11.1 Hospitals, 
    11.2 Specialized Cancer Centers, 
    11.3 Academic Research Institutes, 
    11.4 Biotechnology companies, 
    11.5 Pharmaceutical companies,
12. Antibody Drug Conjugate Market - By Geography (Market Size –$Million/$Billion)
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 Rest of the World
        12.4.1 Middle East
        12.4.2 Africa
        12.4.3 South America
13. Antibody Drug Conjugate Market - Entropy
14. Antibody Drug Conjugate Market – Industry/Segment Competition Landscape Premium 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
        14.1.4 Best Practices for Companies
15. Antibody Drug Conjugate Market – Key Company List by Country Premium Premium
16. Antibody Drug Conjugate Market Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.
List of Tables

Table 1: Antibody Drug Conjugate Market Overview 2019-2024
Table 2: Antibody Drug Conjugate Market Leader Analysis 2018-2019 (US$)
Table 3: Antibody Drug Conjugate Market Product Analysis 2018-2019 (US$)
Table 4: Antibody Drug Conjugate Market End User Analysis 2018-2019 (US$)
Table 5: Antibody Drug Conjugate Market Patent Analysis 2013-2018* (US$)
Table 6: Antibody Drug Conjugate Market Financial Analysis 2018-2019 (US$)
Table 7: Antibody Drug Conjugate Market Driver Analysis 2018-2019 (US$)
Table 8: Antibody Drug Conjugate Market Challenges Analysis 2018-2019 (US$)
Table 9: Antibody Drug Conjugate Market Constraint Analysis 2018-2019 (US$)
Table 10: Antibody Drug Conjugate Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Antibody Drug Conjugate Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Antibody Drug Conjugate Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Antibody Drug Conjugate Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Antibody Drug Conjugate Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Antibody Drug Conjugate Market Value Chain Analysis 2018-2019 (US$)
Table 16: Antibody Drug Conjugate Market Pricing Analysis 2019-2024 (US$)
Table 17: Antibody Drug Conjugate Market Opportunities Analysis 2019-2024 (US$)
Table 18: Antibody Drug Conjugate Market Product Life Cycle Analysis 2019-2024 (US$)
Table 19: Antibody Drug Conjugate Market Supplier Analysis 2018-2019 (US$)
Table 20: Antibody Drug Conjugate Market Distributor Analysis 2018-2019 (US$)
Table 21: Antibody Drug Conjugate Market Trend Analysis 2018-2019 (US$)
Table 22: Antibody Drug Conjugate Market Size 2018 (US$)
Table 23: Antibody Drug Conjugate Market Forecast Analysis 2019-2024 (US$)
Table 24: Antibody Drug Conjugate Market Sales Forecast Analysis 2019-2024 (Units)
Table 25: Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 26: Antibody Drug Conjugate Market By Phase, Revenue & Volume,By Clinical, 2019-2024 ($)
Table 27: Antibody Drug Conjugate Market By Phase, Revenue & Volume,By Pre-Clinical, 2019-2024 ($)
Table 28: Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 29: Antibody Drug Conjugate Market By Availability, Revenue & Volume,By Approved Drugs, 2019-2024 ($)
Table 30: Antibody Drug Conjugate Market By Availability, Revenue & Volume,By Pipeline Drugs, 2019-2024 ($)
Table 31: North America Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 32: North America Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 33: South america Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 34: South america Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 35: Europe Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 36: Europe Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 37: APAC Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 38: APAC Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 39: Middle East & Africa Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 40: Middle East & Africa Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 41: Russia Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 42: Russia Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 43: Israel Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2019-2024 ($)
Table 44: Israel Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2019-2024 ($)
Table 45: Top Companies 2018 (US$)Antibody Drug Conjugate Market, Revenue & Volume
Table 46: Product Launch 2018-2019Antibody Drug Conjugate Market, Revenue & Volume
Table 47: Mergers & Acquistions 2018-2019Antibody Drug Conjugate Market, Revenue & Volume


List of Figures

Figure 1: Overview of Antibody Drug Conjugate Market 2019-2024
Figure 2: Market Share Analysis for Antibody Drug Conjugate Market 2018 (US$)
Figure 3: Product Comparison in Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 4: End User Profile for Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Antibody Drug Conjugate Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Antibody Drug Conjugate Market 2018-2019
Figure 8: Ecosystem Analysis in Antibody Drug Conjugate Market 2018
Figure 9: Average Selling Price in Antibody Drug Conjugate Market 2019-2024
Figure 10: Top Opportunites in Antibody Drug Conjugate Market 2018-2019
Figure 11: Market Life Cycle Analysis in Antibody Drug Conjugate Market
Figure 12: GlobalBy PhaseAntibody Drug Conjugate Market Revenue, 2019-2024 ($)
Figure 13: GlobalBy Availability Antibody Drug Conjugate Market Revenue, 2019-2024 ($)
Figure 14: Global Antibody Drug Conjugate Market - By Geography
Figure 15: Global Antibody Drug Conjugate Market Value & Volume, By Geography, 2019-2024 ($) 
Figure 16: Global Antibody Drug Conjugate Market CAGR, By Geography, 2019-2024 (%)
Figure 17: North America Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 18: US Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 19: US GDP and Population, 2018-2019 ($)
Figure 20: US GDP – Composition of 2018, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2018-2019 ($)
Figure 22: Canada Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 23: Canada GDP and Population, 2018-2019 ($)
Figure 24: Canada GDP – Composition of 2018, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 26: Mexico Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 27: Mexico GDP and Population, 2018-2019 ($)
Figure 28: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 30: South America Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 31: Brazil Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 32: Brazil GDP and Population, 2018-2019 ($)
Figure 33: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 35: Venezuela Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 36: Venezuela GDP and Population, 2018-2019 ($)
Figure 37: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 39: Argentina Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 40: Argentina GDP and Population, 2018-2019 ($)
Figure 41: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 43: Ecuador Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 44: Ecuador GDP and Population, 2018-2019 ($)
Figure 45: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 47: Peru Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 48: Peru GDP and Population, 2018-2019 ($)
Figure 49: Peru GDP – Composition of 2018, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 51: Colombia Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 52: Colombia GDP and Population, 2018-2019 ($)
Figure 53: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 55: Costa Rica Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 56: Costa Rica GDP and Population, 2018-2019 ($)
Figure 57: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 59: Europe Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 60: U.K Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 61: U.K GDP and Population, 2018-2019 ($)
Figure 62: U.K GDP – Composition of 2018, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 64: Germany Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 65: Germany GDP and Population, 2018-2019 ($)
Figure 66: Germany GDP – Composition of 2018, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 68: Italy Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 69: Italy GDP and Population, 2018-2019 ($)
Figure 70: Italy GDP – Composition of 2018, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 72: France Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 73: France GDP and Population, 2018-2019 ($)
Figure 74: France GDP – Composition of 2018, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2018-2019 ($)
Figure 76: Netherlands Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 77: Netherlands GDP and Population, 2018-2019 ($)
Figure 78: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 80: Belgium Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 81: Belgium GDP and Population, 2018-2019 ($)
Figure 82: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 84: Spain Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 85: Spain GDP and Population, 2018-2019 ($)
Figure 86: Spain GDP – Composition of 2018, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 88: Denmark Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 89: Denmark GDP and Population, 2018-2019 ($)
Figure 90: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 92: APAC Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 93: China Antibody Drug Conjugate Market Value & Volume, 2019-2024
Figure 94: China GDP and Population, 2018-2019 ($)
Figure 95: China GDP – Composition of 2018, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2018-2019 ($)Antibody Drug Conjugate Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 97: Australia Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 98: Australia GDP and Population, 2018-2019 ($)
Figure 99: Australia GDP – Composition of 2018, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 101: South Korea Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 102: South Korea GDP and Population, 2018-2019 ($)
Figure 103: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 105: India Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 106: India GDP and Population, 2018-2019 ($)
Figure 107: India GDP – Composition of 2018, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2018-2019 ($)
Figure 109: Taiwan Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 110: Taiwan GDP and Population, 2018-2019 ($)
Figure 111: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 113: Malaysia Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 114: Malaysia GDP and Population, 2018-2019 ($)
Figure 115: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 117: Hong Kong Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 118: Hong Kong GDP and Population, 2018-2019 ($)
Figure 119: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 121: Middle East & Africa Antibody Drug Conjugate Market Middle East & Africa 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 122: Russia Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 123: Russia GDP and Population, 2018-2019 ($)
Figure 124: Russia GDP – Composition of 2018, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 126: Israel Antibody Drug Conjugate Market Value & Volume, 2019-2024 ($)
Figure 127: Israel GDP and Population, 2018-2019 ($)
Figure 128: Israel GDP – Composition of 2018, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 130: Entropy Share, By Strategies, 2018-2019* (%)Antibody Drug Conjugate Market 
Figure 131: Developments, 2018-2019*Antibody Drug Conjugate Market 
Figure 132: Company 1 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 133: Company 1 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 134: Company 1 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 135: Company 2 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 136: Company 2 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 137: Company 2 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 138: Company 3Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 139: Company 3Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 140: Company 3Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 141: Company 4 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 142: Company 4 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 143: Company 4 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 144: Company 5 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 145: Company 5 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 146: Company 5 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 147: Company 6 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 148: Company 6 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 149: Company 6 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 150: Company 7 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 151: Company 7 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 152: Company 7 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 153: Company 8 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 154: Company 8 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 155: Company 8 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 156: Company 9 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 157: Company 9 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 158: Company 9 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 159: Company 10 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 160: Company 10 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 161: Company 10 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 162: Company 11 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 163: Company 11 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 164: Company 11 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 165: Company 12 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 166: Company 12 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 167: Company 12 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 168: Company 13Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 169: Company 13Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 170: Company 13Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 171: Company 14 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 172: Company 14 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 173: Company 14 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 174: Company 15 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 175: Company 15 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 176: Company 15 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)